How does orforglipron at 15 mg weekly compare on cost per milligram across routes?

Stated plainly: orforglipron · 15 mg.

I have worked this out and I would like someone to find the error, because I suspect there is one.

My working so far, for the record, is below, and I am fairly sure the error is in the unit conversion rather than the algebra.

Is my approach right even if my number is wrong?

Put another way, start from what "research use only" actually means, because most of the downstream questions are answered by it. It means no release testing, no pharmacovigilance, no regulatory obligation to you, and no recourse.

What a verification listing at VendorInvestigate or a rating at PeptideMeter actually evidences is that some process was applied — which is more than nothing and considerably less than an audit. The useful question is what the process consists of and whether its inputs are independently obtained samples or vendor-supplied ones.

A parcel sitting for eight to fourteen days at a customs facility is overwhelmingly likely to be queue rather than scrutiny. Volumes at international sorting facilities are high, tracking updates are batched, and a gap in scanning is not evidence of inspection. Escalating during that window generally achieves nothing except creating a record.

The economics of pooled purchasing are not specific to this field, and the failure modes documented in the general literature on informal collective purchasing — organiser default, quality dispute without adjudication, and free-riding on testing costs — are exactly the ones that recur here.

The limitation of the red-flag approach is that it is asymmetric: it identifies bad documentation reliably and good material only weakly.

The evidence you want is boring: the same result, from an independent laboratory, across more than one lot, over more than one year.

Stated carefully, the question to ask is not whether a vendor is good but what evidence exists, of what kind, about which lots, from whom. Reputation is a compression of that evidence and it compresses badly.

Cost per milligram, worked honestly: a 10 mg vial at £34 is £3.40 per nominal milligram. If the content assay says 9.2 mg, that is £3.70 per actual milligram. If you then lose 4 µL of dead space per draw from a 2 mL fill across twenty draws, that is 80 µL or four per cent of the fill, taking you to £3.85. Add a £110 content assay amortised across the vial and it is £14.85 per milligram for the first vial of a new lot and £3.85 thereafter. The testing dominates, which is the actual argument for buying larger lots.

Worth being precise here: the consumer-protection question about a stablecoin transfer has a simple answer: you give up reversibility entirely. There is no chargeback, no acquirer, no dispute process. What you retain is the on-chain record, which proves that a transfer happened and to which address — useful for establishing that you paid, useless for getting the money back. That asymmetry is the whole risk profile.

I would resist treating a long track record as evidence of current quality. Suppliers change synthesis partners, fill sites and staff, and a 2024 result is weak evidence about a 2026 lot.

Assume no recourse and plan accordingly. That assumption is both prudent and, in this context, accurate.

Specifically, evaluate a supplier on the documentation they cannot fabricate cheaply, which in practice means lot-specific certificates from a laboratory that hosts its own reports and a testing history that spans more than one lot.

Personal-importation discretion varies more than people assume. Several jurisdictions operate a published enforcement-discretion policy for small quantities for personal use of unapproved products; several do not, and treat any importation of an unapproved medicinal product as an offence irrespective of quantity. The distinction is jurisdiction-specific and worth checking rather than inferring from a forum consensus.

Regulatory positions on personal importation are published: the relevant frameworks are the US FDA’s personal importation policy in its Regulatory Procedures Manual, the UK MHRA’s guidance on importing medicines for personal use, and the equivalent national provisions in the EU member states and Australia’s Therapeutic Goods Administration personal importation scheme. They differ materially from each other.

The caveat is that none of this makes an unapproved product safe or lawful to use. It reduces one category of uncertainty — what is in the vial — and leaves every other category untouched.

Test the first lot from any new supplier, set your accept threshold before the result arrives, and keep the certificate with the lot number and the date in one place.

In practice, the structural problem with a group buy is that the organiser typically holds both the money and the material, which means there is no point at which any participant has recourse. That is solvable, and it is solved by design rather than by trust.

Lot-to-lot content variation of nine per cent between two nominally identical lots, both within a stated specification, is the single most common finding in independent testing and the least discussed. It is not fraud; it is the consequence of a fill process controlled to a tolerance rather than to a target. It is also the reason a per-lot content assay is worth more than a per-supplier reputation.

The published aggregate datasets from Janoshik, Medutest and PeptideMeter are the closest thing to a systematic evidence base in this space, and the striking pattern across all three is that identity is almost always confirmed, purity is usually acceptable, and content is where the variance lives.

Worth being explicit that this site sells nothing, is not affiliated with any supplier, and has no financial relationship with any vendor discussed. Vendor storefronts are linked from the vendor directory, marked nofollow and sponsored.

Structure the group buy so that no single person is simultaneously the treasurer, the custodian and the arbiter. That one change removes most of the failure modes.